Neuphoria Therapeutics (NEUP) Long-Term Deferred Tax (2023 - 2025)

Neuphoria Therapeutics (NEUP) has reported Long-Term Deferred Tax for 3 consecutive years, with $26.1 million the latest figure, recorded in Q2 2025.

• On a quarterly basis, Long-Term Deferred Tax fell 5.78% year-over-year to $26.1 million in Q2 2025; TTM through Jun 2025 was $26.1 million, a 5.78% decrease from a year earlier, with the FY2025 full-year figure at $26.1 million, down 5.78% from the prior year.
• Long-Term Deferred Tax was $26.1 million for Q2 2025 at Neuphoria Therapeutics, down from $27.7 million in the prior quarter.
• Over five years, Long-Term Deferred Tax peaked at $27.7 million in Q2 2024 and troughed at $23.5 million in Q2 2023.
• A 3-year average of $25.8 million and a median of $26.1 million in 2025 frame the typical range for Long-Term Deferred Tax.
• Across the five-year window, Long-Term Deferred Tax advanced 17.87% in 2024 and declined 5.78% in 2025, its largest moves.
• Over 3 years, Long-Term Deferred Tax stood at $23.5 million in 2023, then increased by 17.87% to $27.7 million in 2024, then fell by 5.78% to $26.1 million in 2025.
• The last three Long-Term Deferred Tax figures came in at $26.1 million (Q2 2025), $27.7 million (Q2 2024), and $23.5 million (Q2 2023), per Business Quant data.